Sato Pharmaceutical Co., Ltd., 1-5-27 Moto-Akasaka Minato-ku Tokyo 107-0051 JapanFEI 3004055563Issued May 18, 2026Center for Drug Evaluation and Research (CDER)
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3004055563.
Violations4
Issue DateMay 18, 2026
Product TypeDrugs
StatusOpen
Letter Details
Firm
Sato Pharmaceutical Co., Ltd.
Location
Sato Pharmaceutical Co., Ltd., 1-5-27 Moto-Akasaka Minato-ku Tokyo 107-0051 Japan
FEI Number
3004055563
Country
Japan
Issue Date
May 18, 2026
Issuing Office
Center for Drug Evaluation and Research (CDER)
Product Type
Drugs
Status
Open
Subject
CGMP/Drugs/Adulterated/OTC
Sato Pharmaceutical Co., Ltd. FDA Warning Letter, May 18, 2026
Talk to a Specialist